Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DLX105-DMP in mild-to-moderate plaque psoriasis
NCT04203433Phase 1Completed
- Sponsor
- DelArrivo, Inc.
- Start
- Mar 2022
- Primary completion
- Sep 2022
- Modality
- Antibody Conjugates, scFv Fragments, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of DLX105 in plaque psoriasis (2 arms), sponsored by DelArrivo, Inc. Primary endpoints: Local Tolerability Sensations up to 4 Weeks, Local Site Application Assessment up to 4 Weeks and 3 more. Started Mar 2022; status: completed.
02
Drugs
DLX105
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT04203433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04203433.